FA B-lipid
16:0 I-lipid
(16:0), O
stearic O
acid O
(18:0), O
and O
soy-derived O
lysophosphatidylcholine O
(LPCsoy) O
(Avanti O
Polar O
Lipids) O
were O
dissolved O
in O
100% O
ethanol O
and O
filter-sterilized O
(10 O
mM O
stock O
solutions). O

ST B-lipid
27:1;O I-lipid
and O
LDL-cholesterol O
also O
showed O
a O
negative O
correlation O
to O
Phe; O
however, O
this O
was O
not O
statistically O
significant. O

Although O
changes O
in O
the O
abundance O
of O
2 O
compounds O
(Propanoic O
acid, O
2-(methoxyimino)-, O
trimethylsilyl O
ester O
and O
FA B-lipid
9:0, I-lipid
trimethylsilyl O
ester O
) O
were O
statistically O
significant O
(unadjusted O
p O
-values O
≤0.05) O
in O
a O
paired-sample O
comparison O
of O
patients O
before O
and O
after O
treatment, O
they O
failed O
to O
meet O
the O
established O
criterion O
of O
FDR. O

Additionally, O
seven O
lysophosphocholines, O
LPC B-lipid
14:0, I-lipid
LPC B-lipid
16:0, I-lipid
LPC B-lipid
18:1, I-lipid
LPC B-lipid
20:2, I-lipid
LPC B-lipid
20:3, I-lipid
LPC B-lipid
20:4 I-lipid
and O
LPC B-lipid
20:5, I-lipid
were O
downregulated O
in O
HCC O
plasma O
relative O
to O
HV O
plasma. O

Identified O
metabolites: O
3, O
alanine; O
6, O
asparagine; O
7, O
aspartic O
acid; O
8, O
betaine; O
9, O
citric O
acid; O
12, O
formic O
acid; O
15, O
glutamic O
acid; O
17, O
glycine; O
20, O
histidine; O
21, O
3-hydroxybutyric O
acid; O
22, O
4-hydroxyproline; O
23, O
2-hydroxyisobutyric O
acid; O
25, O
isoleucine; O
28, O
lactic O
acid; O
31, O
maleic O
acid; O
33, O
malonic O
acid; O
39, O
FA B-lipid
3:0; I-lipid
46, O
tryptophan; O
48, O
valine. O

Our O
results O
show O
that O
a O
number O
of O
lysophosphatidylcholines O
(LysoPCs) O
are O
obviously O
decreased O
and O
free O
fatty O
acids O
(FFA) O
(linoleic O
acid, O
arachidonic O
acid, O
FA B-lipid
20:5, I-lipid
FA B-lipid
22:6, I-lipid
oleic O
acid, O
and O
palmitic O
acid) O
are O
increased O
after O
high-altitude O
exposure O
patients, O
and O
the O
reason O
is O
not O
clear. O

GPCe O
44:4 O
was O
correlated O
only O
with O
GPCe O
38:1, O
and O
GPCe O
30:1 O
was O
correlated O
only O
with O
PC B-lipid
40:2. I-lipid

ATP O
adenosine O
triphosphate, O
Fatty O
acids O
capric O
acid, O
cis-9-palmitoleic O
acid, O
FA B-lipid
12:0, I-lipid
oleic O
acid, O
palmitic O
acid O
or O
stearic O
acid, O
MDD O
major O
depressive O
disorder, O
PUFAs O
FA B-lipid
20:5 I-lipid
(EPA, O
ω-3) O
and O
arachidonic O
acid O
(AA, O
ω-6), O
SAM O
S-adenosylmethionine, O

Interestingly, O
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:3, I-lipid
and O
PC B-lipid
36:2 I-lipid
increased O
in O
both O
tissues O
and O
sera O
of O
MF O
patients, O
whereas O
SM B-lipid
16:0;O2, I-lipid
PC B-lipid
32:0, I-lipid
and O
PC B-lipid
38:4 I-lipid
levels O
increased O
in O
the O
sera O
but O
decreased O
in O
the O
tissues O
of O
MF O
patients O
compared O
to O
control O
subjects. O

Similar O
to O
our O
findings, O
Prakash O
et O
al., O
reported O
significant O
increase O
in O
the O
level O
of O
FA B-lipid
20:4;O, I-lipid
an O
CYP450 O
metabolite O
in O
urine O
treated O
with O
β-glucuronidases, O
and O
they O
concluded O
that O
CYP450 O
metabolites O
are O
predominantly O
excreted O
in O
conjugated O
form. O

Intra- O
and O
inter-assay O
accuracy O
and O
precision O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid

However, O
there O
is O
also O
co-elution O
of O
neutral O
and O
lipid O
compounds; O
testosterone-d_2 O
co-eluted O
with O
17:0 O
Cer, O
and O
PC B-lipid
34:1 I-lipid
co-eluted O
with O
an O
unknown O
compound O
with O
a O
similar O
m/ O

To O
analyze O
FA B-lipid
20:4;O, I-lipid
20 O
HETE, O
11(12)-DiHET O
and O
14(15)-DiHET O
a O
modified O
version O
of O
the O
method O
described O
by O
Mangal O
et O
al. O
was O
used. O

As O
a O
result, O
seven O
“differential O
metabolites” O
were O
identified, O
including: O
PC B-lipid
40:4 I-lipid
(1), O
2-hexenoylcarnitine O
(2), O
beta-D-glucopyranuronic O
acid O
(3), O
DG B-lipid
38:9 I-lipid
(4), O
MG B-lipid
20:3 I-lipid
(5), O
LPC B-lipid
18:2 I-lipid
(6) O
and O
LPC B-lipid
16:0 I-lipid
(7). O

Although O
matrix O
effect O
was O
observed O
for O
Cer B-lipid
22:0;O2 I-lipid
in O
plasma, O
the O
co-elution O
of O
deuterium-labeled O
internal O
standard O
compensated O
the O
matrix O
effect O
and O
the O
accuracy O
and O
precision O
were O
not O
affected. O

In O
the O
validation O
set, O
the O
most O
significant O
difference O
in O
mean O
plasma O
concentration O
was O
PC B-lipid
38:3 I-lipid
(p O
= O
5.70481E-11, O
Student's O
t-test). O

Elevated O
FA B-lipid
20:4;O I-lipid
(12-HETE), O
FA O
20:4;O, O
sphingosine, O
γ-glutamyl O
oxidative O
stress-associated O
metabolites, O
xanthine, O
amino O
acids O
serine, O
glycine O
and O
aspartate, O
and O
a-cylcarnitines O
were O
strongly O
associated O
with O
the O
presence O
of O
HCC. O

However, O
the O
CID O
spectrum O
of O
SM B-lipid
36:3;O2 I-lipid
did O
not O
reveal O
any O
abundant O
ions O
that O
identify O
the O
fatty O
acyl O
substituents. O

Among O
these, O
six O
phosphotidylcholines, O
PC B-lipid
34:2, I-lipid
PC B-lipid
34:1, I-lipid
PC B-lipid
36:3, I-lipid
PC B-lipid
36:2, I-lipid
PC B-lipid
32:0, I-lipid
and O
PC B-lipid
38:4 I-lipid
and O
one O
sphingomyelin, O
SM B-lipid
16:0;O2 I-lipid
were O
altered O
in O
both O
MF O
tissues O
and O
sera. O

In O
our O
study, O
LPE B-lipid
18:1 I-lipid
was O
shown O
significantly O
related O
to O
disease O
status O
with O
increasing O
level O
in O
NSCLC O
patients, O
mainly O
in O
adenocarcinoma O
cases. O

Using O
the O
same O
procedure, O
another O
five-variable O
model O
(AUC = 0.878, O
95% O
CI = 0.792–0.937, O
probability O
3 = exp O
(6.176 + 1.437 O
[FA O
5:0;O I-lipid
[−2.378 O
[5-dihydrotestosterone O
sulfate] O
−2.415 O
[serine] O
−0.022 O
[spermine] O

Abbreviations: O
FA: O
fatty O
acid; O
LPC B-lipid
16:0: I-lipid
1-Palmitoyl-glycero-3-phosphocholine; O
MSA: O
multiple O
system O
atrophy; O
DHEAS: O
dehydroisoandrosterone O
3-sulfate; O
SEM: O
standard O
error O
of O
the O
mean. O

Oxylipins O
might O
be O
produced O
by O
the O
kidney O
because O
FA B-lipid
20:4;O I-lipid
in O
the O
blood O
stream O
was O
not O
directly O
secreted O
into O
the O
urine O
in O
a O
previous O
study. O

Plasma O
FA B-lipid
20:4;O I-lipid
and O
plasma O
DHETs O
were O
positively O
correlated O
only O
when O
all O
of O
the O
subjects O
were O
included O
(r O
_s O
=0.538; O
P O
=0.002; O
please O
see O
). O

The O
method O
was O
quantitatively O
characterized O
in O
human O
plasma O
with O
good O
linearity O
(R O
= O
0.990–0.999), O
acceptable O
reproducibility O
(relative O
standard O
deviation O
(RSD) O
< O
20% O
for O
the O
majority O
of O
analytes), O
accuracy O
(67.8 O
to O
129.3%) O
for O
all O
analytes, O
and O
recovery O
(66.8–121.2%) O
for O
all O
analytes O
except O
FA B-lipid
20:4;O. I-lipid

Glyoxylate O
and O
dicarboxylate O
metabolism O
(glycolic O
acid; O
impact O
= O
0.007), O
tryptophan O
metabolism O
(tryptophan; O
impact O
= O
0.109), O
linoleic O
acid O
metabolism O
(linoleic O
acid O
and O
FA B-lipid
18:2;O; I-lipid
impact O
= O
0.656), O
fatty O
acid O
metabolism O
(palmitoylcarnitine O
and O
palmitic O
acid; O
impact O
= O
0.030), O
phenylalanine, O
tyrosine O
and O
tryptophan O
biosynthesis O
(tryptophan, O
tyrosine, O
and O
phenylalanine; O
impact O
= O
0.008), O
α-linolenic O
acid O
metabolism O
(α-linolenic O
acid; O
impact O
= O
0.203), O
arachidonic O
acid O
metabolism O
(5-HETE, O
leukotriene O
B4, O
and O
arachidonic O
acid; O
impact O
= O
0.226), O
tyrosine O
metabolism O
(tyrosine; O
impact O
= O
0.047), O
phenylalanine O
metabolism O
(tyrosine O
and O
phenylalanine; O
impact O
= O
0.119) O
were O
relevant O
to O
incidence O
of O
LC. O

Another O
study, O
comprising O
of O
30,252 O
breast O
cancer O
patients, O
revealed O
that O
FA B-lipid
20:5 I-lipid
and O
FA B-lipid
22:6 I-lipid
were O
significantly O
inversely O
associated O
with O
risk O
for O
breast O
cancer O
(HR: O
0.70, O
95% O
CI: O
0.54–0.90; O
HR: O
0.67, O
95% O
CI: O
0.52–0.87). O

The O
MS/MS O
(m/z O
792.5408) O
confirmed O
that O
PE B-lipid
40:5 I-lipid
is O
present O
and O
predominantly O
in O
the O
form O
of O
the O
molecular O
species O
PE O
40:5, O
confirmed O
by O
the O
detected O
acyl O
anions O
(data O
not O
shown). O

Scatter O
plots O
are O
shown O
for O
total O
GM3 O
(A), O
and O
for O
the O
GM3 O
species O
GM3 B-lipid
42:2;O2 I-lipid
(B) O
and O
GM3 B-lipid
44:1;O2 I-lipid
(C). O

Oral O
high O
fat O
supplementation-induced O
upregulation O
of O
LysoPC O
metabolites, O
including O
LPC B-lipid
16:0, I-lipid
might O
have O
yielded O
beneficial O
health O
effects O
in O
postoperative O
pancreatic O
cancer O
patients. O

The O
levels O
of O
10-hydroxyldocosahexaenoic O
acid O
(HDoHE), O
12- O
hydroxyeicosapentaenoic O
acid O
(HEPE), O
and O
FA B-lipid
22:6;O I-lipid
were O
significantly O
higher O
in O
female O
urine. O

Importantly, O
FA B-lipid
10:0, I-lipid
FA B-lipid
6:0 I-lipid
and O
6-pentyloxan-2-one O
were O
absent O
in O
the O
cellular O
medium, O
suggesting O
its O
origin O
from O
cellular O
metabolism, O
thus O
unveiling O
great O
potential O
as O
candidate O
biomarkers O
to O
be O
further O
validated O
in O
biofluids O
from O
PCa O
patients. O

Lipidomix O
Mass O
Spec O
Standard O
(Catalogue O
No. O
330707, O
containing O
160 μg/mL O
PC B-lipid
33:1 I-lipid
(d7)) O
was O
purchased O
from O
Avanti O
Polar O
lipids O
(Alabaster, O
AL, O
USA). O

In O
addition, O
especially, O
depletion O
of O
FA B-lipid
22:6 I-lipid
(C22:6) O
may O
influence O
on O
homeostasis O
of O
liver O
tissue, O
likely O
fibrosis O
progression. O

As O
shown O
in O
Table O
, O
these O
included O
lysophosphatidylcholines O
(LPCs) O
[LPC O
16:0, I-lipid
LPC B-lipid
18:0, I-lipid
LPC B-lipid
18:2], I-lipid
lysophosphatidylethanolamines O
(LPEs) O
[LPE O
20:0], I-lipid
PC B-lipid
34:2, I-lipid
LPC B-lipid
O-16:0, I-lipid
PC B-lipid
36:2, I-lipid
PC B-lipid
32:0, I-lipid
PC B-lipid
36:3, I-lipid
PC B-lipid
38:4, I-lipid
PC B-lipid
34:1 I-lipid
and O
SM B-lipid
16:0;O2. I-lipid

These O
would O
have O
had O
a O
severe O
adverse O
impact O
on O
the O
identification O
of O
C=C O
locations O
in O
PE B-lipid
39:4 I-lipid
if O
PB–MS/MS O
analysis O
was O
directly O
applied O
to O
the O
lipid O
extract. O

(C–E) O
Circulating O
PC, O
containing O
linoleic O
acids O
(PC O
34:2, O
PC B-lipid
36:2, I-lipid
PC B-lipid
38:2) I-lipid
and O
α-linolenic O
acids O
(PC O
34:3, O
PC B-lipid
36:3, I-lipid
PC B-lipid
38:3), I-lipid
are O
compared O
between O
hypertensive O
and O
normotensive O
NAFLD O
patients. O

For O
instance, O
C=C O
isomer O
compositional O
analysis O
revealed O
that O
PE B-lipid
34:1 I-lipid
consisted O
of O
two O
C=C O
location O
isomers, O
PE O
16:0_18:1(Δ9) O
and O
PE O
16:0_18:1(Δ11) O

Specifically, O
they O
analyzed O
FA B-lipid
20:4;O, I-lipid
total O
epoxyeicosatrienoic O
acids O
(EET) O
and O
dihydroxyeicotatriennoic O
acids O
(DiHETEs) O
in O
396 O
patients O
with O
ischemic O
stroke O
and O
carotid O
plaque. O

Wang O
et O
al. O
also O
observed O
lower O
concentrations O
of O
unsaturated O
LPC, O
LPC B-lipid
18:1, I-lipid
and O
LPC B-lipid
18:2 I-lipid
in O
overweight/obese O
adults O
than O
in O
nonobese O
adults. O

Plasma O
FA B-lipid
20:4;O I-lipid
was O
highest O
in O
subjects O
with O
renovascular O
disease O
(median: O
1.20 O
ng/mL; O
range: O
0.42 O
to O
1.92 O
ng/mL) O
compared O
with O
subjects O
with O
essential O
hypertension O
(median: O
0.90 O
ng/mL; O
range: O
0.40 O
to O
2.17 O
ng/mL) O
and O
control O
subjects O
(median: O
0.45 O
ng/mL; O
range: O
0.14 O
to O
1.70 O
ng/mL; O
P O
<0.05). O

The O
earlier O
eluting O
isomer O
of O
PC B-lipid
38:4 I-lipid
gave O
rise O
to O
the O
fragment O
ions O
504.3, O
528.3 O
and O
534.3, O
matching O
with O
the O
potential O
fragmentation O
pattern O
of O
PC O
38:4. O

FA B-lipid
4:0 I-lipid
is O
a O
short-chain O
fatty O
acids O
mainly O
generated O
from O
dietary O
cellulose, O
starch O
and O
other O
undigested O
substances O
under O
microbial O
fermentation O
in O
the O
cecum O
or O
colon O
(Mao O
et O
al., O
2012). O

This O
is O
in O
line O
with O
past O
literature O
reporting O
an O
increase O
in O
FA B-lipid
10:0 I-lipid
42 days O
after O
RYGB.31 O
FA O
10:0 O
is O
a O
medium O
chain O
FA O
(MCFA). O

However, O
the O
unique O
fragment O
ions O
m/z O
149, O
m/z O
153 O
and O
m/z O
205 O
for O
FA B-lipid
22:6;O, I-lipid
FA O
22:6;O O
and O
FA O
22:6;O, O
respectively, O
can O
be O
easily O
identified O
by O
visually O
inspecting O
the O
heatmap. O

A O
stable O
FA B-lipid
20:4;O I-lipid
agonist O
induced O
activation O
of O
the O
small-GTPase O
Ras O
in O
HRPTEC O
cells. O

A O
study O
by O
Calejo O
et O
al O
revealed O
that O
FAL B-lipid
5:0 I-lipid
had O
a O
higher O
level O
of O
concentration O
in O
the O
urine O
samples O
of O
smokers O
compared O
with O
non-smokers. O

ABCD2 O
+ O
LAA O
+ O
LPC B-lipid
20:4 I-lipid
= O
0.711, O
p O
< O
0.001; O
integrated O
discrimination O
improvement O
(IDI) O
test O
for O
comparison O
of O
prediction O
models: O
p O
< O
0.0001). O

The O
VIP O
plot O
(Figure O
), O
sorted O
by O
importance, O
showed O
the O
metabolites O
tryptophan O
and O
FA B-lipid
4:0;O I-lipid
as O
most O
discriminatory O
between O
GDM O
and O
control. O

The O
serum O
levels O
of O
FA B-lipid
12:0, I-lipid
pinitol, O
maltol, O
sucrose, O
and O
S13 O
were O
significantly O
higher O
after O
soy O
drink O
intake O
than O
after O
milk O
and O
cheese O
intake O
at O
1, O
2, O
and O
4 O
h O
(see O
Tables O
S3 O
and O
S4). O

Glycoprotein O
acetyls, O
ketone O
bodies, O
glucose, O
and O
FA B-lipid
22:6 I-lipid
were O
associated O
with O
all O
3 O
diseases. O

In O
addition, O
Ward O
et O
al. O
suggested O
that O
FA B-lipid
20:4;O I-lipid
plays O
a O
role O
in O
the O
pathophysiology O
of O
acute O
ischaemic O
stroke O
and O
subsequent O
clinical O
outcome. O

The O
present O
finding O
of O
elevated O
expression O
of O
CYP4A/F O
enzymes O
in O
human O
cancer O
tissue O
suggests O
that O
FA B-lipid
20:4;O I-lipid
inhibitors O
and O
antagonists O
may O
be O
useful O
in O
the O
treatment O
of O
cancer. O

In O
this O
context O
malondialdehyde, O
FAL B-lipid
9:0;O, I-lipid
FAL B-lipid
3:0 I-lipid
and O
FAL B-lipid
6:0 I-lipid
have O
been O
described O
as O
suitable O
markers O
[, O
]. O

We O
observed O
here O
SM B-lipid
36:3;O2 I-lipid
as O
a O
marker O
of O
TFA O
intake. O

The O
results O
demonstrated O
that O
the O
phosphatidic O
acid O
and O
SE B-lipid
27:1/18:0 I-lipid
levels O
in O
HU O
were O
lower O
than O
those O
in O
HU+NAFLD; O
by O
contrast, O
the O
inosine O
levels O
in O
HU O
were O
higher O
than O
those O
in O
HU+NAFLD. O

We O
observed O
that O
circulating O
levels O
of O
FA B-lipid
20:4;O I-lipid
were O
significantly O
higher O
in O
patients O
with O
atheroma O
plaque O
than O
in O
healthy O
subjects O
(p O
= O
0.018). O

Kynurenine, O
Acetylcarnitine, O
PC B-lipid
42:11, I-lipid
and O
LPE B-lipid
20:0 I-lipid
were O
selected O
as O
the O
vital O
survival O
potential O
predictive O
biomarkers. O

The O
compositional O
changes O
of O
the O
C18:1 O
Δ9 O
and O
Δ11 O
isomers O
of O
PC B-lipid
33:1 I-lipid
were O
not O
statistically O
different O
between O
the O
normal O
and O
cancerous O
tissue O
samples. O

For O
the O
endogenous O
metabolites, O
similar O
amounts O
of O
oleic O
acid O
(p=0.33), O
linoleic O
acid O
(p=0.49) O
SM B-lipid
34:0;O2 I-lipid
(p=0.53) O
and O
PC B-lipid
34:1 I-lipid
(p=0.38) O
were O
extracted O
using O
either O
method. O

Circulating O
FA B-lipid
20:4;O I-lipid
was O
positively O
correlated O
with O
PRA O
in O
RVD O
and O
may O
contribute O
to O
elevation O
of O
blood O
pressure O
by O
increasing O
vasomotion O
and O
enhancing O
vascular O
reactivity. O

FA B-lipid
10:1;O2 I-lipid
is O
a O
dicarboxylic O
acid. O

Drift O
of O
retention O
time O
of O
each O
peak O
was O
minimized O
by O
locking O
FA B-lipid
17:0 I-lipid
at O
36.00 min O
with O
retention O
time O
locking O
technology O
(RTL, O
Agilent). O

Stability O
of O
the O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
the O
human O
plasma O
was O
evaluated O
under O
a O
variety O
of O
conditions O
to O
establish O
length O
of O
storage O
and O
sample O
processing O
conditions O
(see O
). O

At O
least O
three O
examples O
are O
available, O
albeit O
with O
different O
degrees O
of O
support: O
(a) O
urinary O
p O
-cresol O
amounts O
were O
found O
correlated O
with O
ASD O
severity O
or O
with O
the O
intensity O
of O
stereotypic O
behaviors O
in O
young O
autistic O
children; O
(b) O
i.c.v. O
injection O
of O
FA B-lipid
3:0, I-lipid
an O
enteric-derived O
short O
chain O
fatty O
acid, O
produces O
ASD-like O
behaviors O
in O
the O
rat; O
(c) O
indoxyl O
sulfate O
is O
a O
known O
risk O
factor O
for O
cognitive O
impairment O
in O
chronic O
renal O
disease: O
its O
influx O
across O
the O
blood-brain O
barrier O
using O
the O
organic O
anion O
transporter O
3 O
significantly O
reduces O
the O
efflux O
of O
various O
neurotransmitter O
metabolites O
through O
the O
same O
transporter, O
leading O
to O
their O
accumulation. O

N-3 O
polyunsaturated O
fatty O
acids, O
such O
as O
FA B-lipid
22:6 I-lipid
(22:6), O
are O
precursors O
of O
molecules O
implicated O
in O
the O
resolving O
phase O
of O
inflammation. O

PC B-lipid
34:1, I-lipid
PC(14:0/22:4 O
(7Z,10Z,13Z,16Z)), O
and O
PC B-lipid
36:1. I-lipid

, O
For O
instance, O
the O
sn O
-purity O
of O
the O
PC B-lipid
34:1 I-lipid
sample O
is O
93 O
± O
2%, O
meaning O
that O
it O
contains O
7 O
± O
2% O
PC O
34:1. O

For O
instance O
valine O
is O
strongly O
metabolised O
inside O
the O
mitochondria O
(approximately O
by O
80%) O
to O
produce O
CoA B-lipid
3:0, I-lipid
which O
is O
finally O
transformed O
into O
OAA O
(Fig. O

While O
these O
higher O
amounts O
were O
most O
notable O
for O
FA B-lipid
20:4;O I-lipid
and O
17-HDHA, O
even O
these O
differences O
were O
not O
significant. O

The O
results O
revealed O
all O
analytes O
except O
FA B-lipid
20:4;O I-lipid
are O
stable O
in O
the O
reconstitute O
solution O
at O
4 O
°C O
within O
the O
duration O
of O
24 O
h. O

Centenarians O
displayed O
higher O
circulating O
levels O
of O
FA B-lipid
20:4;O I-lipid
(15-HETE), O
a O
major O
product O
of O
15-lipoxygenase O
(15-LOX) O
enzyme, O
known O
for O
its O
anti-inflammatory O
properties O
. O

The O
PS O
ratio O
trend O
remained O
similar O
when O
PS B-lipid
38:4 I-lipid
was O
divided O
by O
the O
sum O
of O
all O
PS O
lipids O
(SI O
Appendix O
, O
Fig. O

PE O
(P-16 : 0/14 : 0) O
and O
FA B-lipid
19:1;O3 I-lipid
were O
all O
downregulated O
in O
the O
newly O
diagnosed O
T2DM O
group O
with O
fold O
changes O
at O
3.88 O
and O
2.65, O
respectively. O

Of O
the O
nine O
PCs O
associated O
with O
obesity, O
seven O
were O
available O
for O
replication O
and O
five O
(71%), O
including O
PC B-lipid
38:3, I-lipid
replicated O
(Supplementary O
Table O
2). O

Moreover, O
the O
levels O
of O
cholesterol, O
glucopyranose, O
linoleic O
acid, O
glyceric O
acid, O
alanine, O
FA B-lipid
4:1;O2, I-lipid
phosphoric O
acid, O
galactose, O
lactic O
acid, O
glycine, O
glucose, O
proline O
and O
stearic O
acid O
were O
identified O
relevant O
to O
the O
differentiation O
between O
the O
ELS/MDD O
and O
non-ELS/MDD. O

To O
monitor O
and O
quantify O
levels O
of O
the O
SPMs O
derived O
from O
arachidonic O
acid, O
FA B-lipid
22:6 I-lipid
(DHA) O
and O
FA B-lipid
20:5 I-lipid
(EPA) O
in O
plasma O
samples O
, O
, O
multiple O
reaction O
monitoring O
(MRM) O
for O
signature O
ion O
fragments O
was O
performed O
with O
identification O
accomplished O
using O
LC O
retention O
time O
(RT) O
and O
≥6 O
diagnostic O
ions O
of O
MS/MS O
spectrum. O

LPC B-lipid
16:0 I-lipid
did O
not O
show O
a O
significant O
decrease O
after O
heating O
at O
250 O
°C O
for O
60 O
s; O
though O
it O
decreased O
rapidly O
after O
300 O
s. O

For O
instance, O
17 O
metabolites O
that O
potentially O
participate O
in O
Asp O
metabolism, O
ammonia O
recycling, O
protein O
biosynthesis, O
and O
Trp O
metabolism, O
which O
supports O
the O
environment O
needed O
for O
tumorigenesis O
(Figure O
B), O
were O
only O
quantified O
in O
the O
CRC O
group, O
i.e., O
Lys, O
FA B-lipid
7:1;O2 I-lipid
(a O
precursor O
of O
Lys), O
norvaline, O
and O
several O
amino O
acid O
and O
organic O
acid O
derivatives O
(Supplementary O
Table O
). O

[M + H]_+ O
of O
PC B-lipid
34:1. I-lipid

This O
is O
especially O
evident O
for O
FAL B-lipid
16:1;O I-lipid
(ESM O
Fig. O
S6). O

SPMs O
are O
multiple O
hydroxylated O
fatty O
acids O
including O
resolvins, O
maresins, O
and O
protectins O
derived O
from O
the O
n3 O
PUFA O
FA B-lipid
20:5 I-lipid
(EPA) O
and O
FA B-lipid
22:6 I-lipid
(DHA) O
as O
well O
as O
lipoxins O
derived O
from O
arachidonic O
acid O
(ARA). O

Additionally, O
inhibition O
of O
the O
synthesis O
and O
actions O
of O
FA B-lipid
20:4;O I-lipid
with O
HET0016 O
and O
WIT002 O
(FA O
20:4;O O
antagonist) O
inhibits O
the O
proliferation O
of O
renal O
adenocarcinoma O
cells O
in O
vitro O
and O
the O
growth O
of O
kidney O
cancer O
tumors O
in O
an O
animal O
model O
in O
vivo O
. O

Increased O
activation O
of O
cytochrome O
P450 O
pathway O
in O
centenarians O
is O
further O
supported O
by O
increased O
circulating O
levels O
of O
8,9-epoxyeicosatrienoic O
(8,9-EpETrE) O
and O
decreased O
concentration O
of O
FA B-lipid
20:3;O2 I-lipid
(FA O
20:3;O2). O

PC B-lipid
34:1 I-lipid
was O
one O
of O
the O
most O
abundant O
species O
in O
breast O
tissue O
and O
it O
was O
identified O
to O
consist O
of O
sn O
-isomers O
and O
CC O
location O
isomers O
(Δ9 O
vs. O
Δ11 O
in O
C18:1). O

Propionate O
and O
CoA B-lipid
3:0 I-lipid
are O
detoxified O
by O
the O
mitochondria O
through O
the O
methyl-malonyl-CoA O
pathway. O

Measurements O
were O
performed O
in O
two O
subsets O
of O
the O
total O
study O
population O
in O
the O
ST B-lipid
27:1;O I-lipid
and O
Pharmacogenetics O
(CAP) O
study: O
Full O
Range O
of O
Response O
(FR), O
and O
Good O
and O
Poor O
Responders O
(GPR) O
were O
100 O
individuals O
randomly O
selected O
from O
across O
the O
entire O
range O
of O
LDL-C O
responses O
in O
CAP. O

ROC O
curves O
for O
the O
combination O
of O
FA B-lipid
5:0;O, I-lipid
5-dihydrotestosterone O
sulfate, O
serine, O
spermine, O
and O
xanthine. O

(B) O
Histograms O
show O
the O
amount O
of O
PC B-lipid
34:1, I-lipid
PC B-lipid
36:2 I-lipid
and O
PC B-lipid
40:4 I-lipid
expressed O
as O
equivalent O
of O
Internal O
Standard O
(µg/mL) O
along O
the O
paper O
strip. O

We O
also O
conducted O
a O
random O
forest O
analysis O
and O
found O
that O
FA B-lipid
20:4;O I-lipid
was O
the O
main O
differentiator O
in O
the O
list O
of O
selected O
metabolites. O

In O
an O
earlier O
study O
by O
Williams O
et al., O
breast O
cancer O
cells O
were O
found O
to O
contain O
relatively O
increased O
concentrations O
of O
PC B-lipid
34:1 I-lipid
compared O
to O
healthy O
counterparts O
(Williams O
et al., O
1993 O
Apr). O

FA B-lipid
20:4;O2 I-lipid
was O
found O
to O
be O
significant O
owing O
to O
its O
apparent O
complete O
depletion O
in O
serum O
of O
CLL O
patients. O

Before O
analysis, O
lipids O
were O
extracted O
from O
plasma O
(10 O
µl) O
with O
chloroform/methanol O
(2:1; O
20 O
vol) O
following O
the O
addition O
of O
internal O
standards: O
100 O
pmol O
each O
of O
ceramide O
17:0 O
(Matreya O
Inc., O
Pleasant O
Gap, O
PA), O
PC B-lipid
26:0 I-lipid
and O
lysophosphatidylcholine O
(LPC) O
13:0; O
1000 O
pmol O
each O
of O
free O
cholesterol O
(Avanti O
Polar O
Lipids, O
Alabaster, O
AL) O
and O
cholesterol O
ester O
18:0- O
(CDN O
Isotopes, O
Pointe-Claire, O
Quebec, O
Canada); O
and O
100 O
pmol O
triglyceride O
(TG) O
17:0/17:0/17:0 O
and O
200 O
pmol O
diacylglycerol O
(DAG) O
15:0/15:0 O

In O
this O
study, O
FA B-lipid
20:5;O, I-lipid
one O
product O
of O
arachidonic O
acid, O
is O
increased O
after O
high-altitude O
exposure, O
which O
may O
contribute O
to O
the O
severe O
AMS. O

The O
overall O
time O
to O
recurrence O
for O
recurrence O
in O
those O
patients O
with O
predicted O
probability O
below O
the O
cut-off O
value, O
was O
significantly O
lower O
than O
those O
with O
LPG B-lipid
20:5 I-lipid
value O
above O
the O
cut-off O
value O
(30 O
vs O
62 O
months) O
(Figure O
). O

The O
differentiating O
FA O
included O
palmitic O
(16:0), O
oleic O
(18:1), O
linoleic O
(18:2) O
and O
arachidonic O
acids O
(20:4), O
as O
well O
as O
FA B-lipid
20:4;O, I-lipid
which O
have O
been O
proposed O
as O
potential O
biomarkers O
in O
breast O
cancer O
[, O
]. O

None O
of O
the O
analyzed O
samples O
contained O
signals O
representing O
a O
relevant O
interference O
with O
the O
selected O
internal O
standards O
(IS) O
DG O
40:0, O
TG B-lipid
51:0, I-lipid
and O
TG B-lipid
57:0 I-lipid
(ESM O
Fig. O

DG B-lipid
36:6, I-lipid
DG O
38:0, O
TG B-lipid
54:2, I-lipid
and O
TG B-lipid
54:1 I-lipid
were O
spiked O
at O
six O
different O
concentrations O
(ESM O
Fig. O

JWH-073 O
hydroxyindole, O
JWH-200 O
5-hydroxyindole, O
and O
JWH-210 O
FA B-lipid
5:0 I-lipid
were O
not O
detected, O
even O
when O
samples O
contained O
other O
metabolites O
originating O
from O
the O
same O
parent O
compound. O

Eleven O
metabolites O
(FA O
5:0;N, I-lipid
adenosine, O
betaine, O
carnitine, O
creatinine, O
deoxyguanosine, O
D-glutamic O
acid, O
glycerophosphocholine, O
L-valine, O
n-pentadecylamine, O
and O
taurine) O
were O
significantly O
increased O
in O
the O
AF O
group O
relative O
to O
the O
levels O
in O
the O
non-AF O
group, O
whereas O
the O
13 O
remaining O
metabolites O
(butyrylcarnitine, O
choline, O
dimethylglycine, O
guanosine, O
hypoxanthine, O
L-acetylcarnitine, O
L-alanine/sarcosine, O
L-alpha-aminobutyric O
acid, O
L-arginine, O
L-histidine, O
L-proline, O
niacinamide, O
and O
pantothenic O
acid) O
were O
all O
decreased O
(Supplementary O
Table _S1 O
). O

The O
continuous O
line O
represents O
urine O
sphingosine O
and O
the O
dashed O
line O
represents O
serum O
S1P. O
We O
also O
examined O
the O
correlation O
between O
the O
SL O
metabolites O
at O
the O
basal O
status O
and O
FA B-lipid
20:4;O I-lipid
which O
has O
been O
known O
to O
be O
as O
a O
diagnostic O
biomarker O
for O
AERD. O

Only O
fragmentation O
experiments O
in O
the O
negative O
ion O
mode O
enabled O
to O
distinguish O
between O
the O
alkyl-acyl O
form O
PC32e:1 O
by O
the O
presence O
of O
the O
FA B-lipid
16:1 I-lipid
(m/z O
253.2172) O
at O
9.0 min O
(Fig. O

Following O
our O
previous O
procedure, O
each O
100 O
μ O
L O
of O
serum O
sample O
spiked O
with O
two O
internal O
standards O
(10 O
μ O
L O
of O
L-2-chlorophenylalanine O
in O
water, O
0.3 O
mg/mL; O
10 O
μ O
L O
of O
FA B-lipid
17:0 I-lipid
in O
methanol, O
1 O
mg/mL) O
was O
used O
for O
metabolite O
extraction O
with O
300 O
μ O
L O
of O
methanol:chloroform O
(3:1) O
at O
−20 O
°C O
for O
10 O
min. O

This O
spectrum O
matched O
well O
with O
the O
MS/MS O
spectrum O
of O
the O
standard O
FA B-lipid
20:4 I-lipid
available O
in O
the O
Metline O
database. O

The O
area O
ratio O
of O
ion O
abundance O
in O
the O
peaks O
of O
interest O
to O
internal O
standards O
were O
compared O
with O
standard O
curves O
generated O
over O
a O
range O
from O
0.2 O
to O
10 O
ng O
for O
FA B-lipid
20:4;O I-lipid
and O
from O
1.0 O
to O
10 O
ng O
for O
other O
metabolites O
in O
order O
to O
quantify O
the O
production O
of O
FA O
20:4;O O
and O
other O
eicosanoids. O

Indeed, O
in O
this O
study O
we O
observed O
that O
LPI B-lipid
16:1 I-lipid
significantly O
improved O
risk O
prediction O
of O
type O
2 O
diabetes, O
which O
also O
confirmed O
our O
previous O
finding O
that O
LPI O
16:1 O
can O
be O
an O
early O
predictor O
for O
type O
2 O
diabetes. O

Additionally, O
the O
value O
of O
filtering O
the O
negative O
ion O
CTS O
data O
in O
two O
dimensions O
for O
both O
product O
ion O
m/z O
(241.012±10 O
ppm) O
and O
product O
ion O
CCS O
(134±1 O
Å_2 O
) O
was O
further O
demonstrated O
with O
phosphatidylinositol O
lipids O
in O
human O
serum O
and O
allowed O
for O
the O
identification O
of O
PI B-lipid
34:2 I-lipid
at O
m/z O
833, O
PI B-lipid
36:4 I-lipid
at O
m/z O
857, O
PI B-lipid
36:2 I-lipid
at O
m/z O
861, O
and O
PI B-lipid
38:4 I-lipid
at O
m/z O
885 O
from O
the O
negative O
ion O
CTS O
data. O

Activation O
of O
Ras O
in O
human O
proximal O
tubule O
epithelial O
cells O
(HRPTEC) O
treated O
with O
stable O
agonist O
of O
FA B-lipid
20:4;O I-lipid
was O
measured O
using O
a O
Ras O
pull-down O
detection O
kit. O

FA B-lipid
18:2 I-lipid
gradually O
degraded O
under O
250 O
°C O
heating, O
and O
∼50% O
disappeared O
after O
heating O
for O
60 O
s O
(Figure O
S3). O

One O
of O
the O
lipids O
with O
a O
relatively O
high O
degree O
of O
saturation O
which O
increased O
in O
concentration O
in O
the O
fish O
oil O
supplemented O
group O
was O
SM B-lipid
38:2;O2. I-lipid

520.36 O
Da] O
and O
LPC B-lipid
18:1 I-lipid

Proportional O
amounts O
of O
LPC B-lipid
15:0 I-lipid
were O
positively O
associated O
with O
both O
TC O
(r O
= O
0.64, O
p O
= O
0.004) O

When O
the O
severe O
group O
only O
was O
considered, O
two O
lipid O
metabolites O
(TG O
42:2 I-lipid
and O
TG B-lipid
42:1), I-lipid
were O
positively O
correlated O
with O
parasitaemia O
and O
16 O
exhibited O
a O
negative O
correlation. O

This O
is O
of O
interest, O
as O
several O
PE O
species, O
such O
as O
PE B-lipid
38:6 I-lipid
or O
PE B-lipid
40:4, I-lipid
have O
been O
reported O
to O
be O
up-regulated O
in O
CRC O
tissues O
as O
compared O
to O
normal O
tissues. O

Low O
and O
high O
energy O
spectra O
for O
coeluting O
TG B-lipid
52:4 I-lipid
and O
TG B-lipid
54:5 I-lipid
species, O
displaying O
neutral O
losses O
(NL) O
and O
fragments O
indicative O
of O
fatty O
acyl O
chains O
16:0, O
18:0, O
18:1, O
18:2, O
and O
18:3 O
acyl O
chains. O

The O
upregulation O
of O
SM B-lipid
42:1;O2 I-lipid
by O
oral O
high O
fat O
supplementation O
might O
have O
contributed O
to O
the O
overall O
health O
benefits O
of O
the O
HFS O
in O
postoperative O
pancreatic O
cancer O
patients, O
but O
further O
studies O
are O
warranted O
to O
confirm O
this O
finding. O

show O
the O
chromatograms O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
human O
plasma O
with O
internal O
standards. O

shows O
the O
highest O
calibrator O
(ULOQ, O
6/24 O
μg/mL O
of O
Cer B-lipid
22:0;O2/Cer I-lipid
24:0;O2) I-lipid
without O
internal O
standards, O
and O
the O
contribution O
from O
[M+4+H]_+ O
isotope O
peaks O
of O
Cer O
22:0;O2 O
and O
Cer O
24:0;O2 O
were O
less O
than O
0.1% O
of O
the O
those O
of O
their O
internal O
standards. O

Through O
inactivation O
or O
immediate O
metabolism O
to O
20-OH-FA O
20:4;O2, I-lipid
this O
could O
explain O
the O
absence O
of O
FA O
20:4;O2 O
in O
the O
serum O
samples O
from O
patients O
studied O
in O
our O
investigation. O

Thus, O
FA B-lipid
20:5 I-lipid
(C20:5) O
and O
FA B-lipid
20:5;O I-lipid
may O
become O
a O
potent O
biomarker O
for O
prediction O
LC O
development. O

The O
strongest O
positive O
correlator O
with O
the O
measured O
ex O
vivo O
VCAM-1 O
surface O
expression O
was O
Cluster O
1, O
which O
consisted O
predominantly O
of O
EPA O
and O
esterified O
EPA-derived O
metabolites O
(FA O
20:5;O, I-lipid
FA O
20:5;O, O
FA O
20:5;O, O
5-HEPE). O

LPC O
profiling O
revealed O
statistically O
significant O
downregulation O
of O
LPC B-lipid
16:0 I-lipid
in O
HCC O
relative O
to O
AML O
(P<0.001) O
and O
HV O
(P<0.05). O

Only O
trace O
amounts O
of O
Cer B-lipid
42:1;O2, I-lipid
cholesterol, O
and O
TG B-lipid
52:4 I-lipid
were O
found O
in O
methanol-ethanol O
samples O
and O
these O
compounds O
were O
not O
detected O
when O
only O
methanol O
was O
used. O

We O
have O
previously O
published O
data O
from O
the O
ST B-lipid
27:1;O I-lipid
and O
Pharmacogenetics O
(CAP) O
study O
that O
detailed O
the O
association O
of O
metabolites, O
particularly O
lipids O
and O
amino O
acids, O
to O
simvastatin-induced O
cholesterol O
lowering O
in O
patients O
classified O
as O
good O
and O
poor O
responders O
as O
well O
as O
in O
full O
range O
responders O
(; O
). O

As O
far O
as O
we O
know, O
no O
previous O
studies O
have O
focused O
on O
the O
role O
of O
LPC B-lipid
22:6 I-lipid
on O
carotid O
plaque O
formation O
or O
stability O
but O
increased O
levels O
in O
symptomatic O
LAA O
patients O
could O
point O
to O
a O
role O
in O
this O
processes. O

[, O
, O
], O
LPC B-lipid
20:4 I-lipid
[, O
], O
LPE B-lipid
18:0, I-lipid
LPE B-lipid
18:1. I-lipid

From O
, O
SM B-lipid
16:0;O2 I-lipid
and O
SM B-lipid
22:0;O2 I-lipid
were O
identified O
only O
in O
the O
extracts O
of O
protocols O
(i)–(iv), O
but O
could O
not O
be O
identified O
from O
protocols O
(v) O
and O
(vi). O

Their O
final O
concentrations O
in O
sample O
extracts O
were; O
1.6 O
μM O
of O
LPC O
17:0, O
PC B-lipid
34:0, I-lipid
PA B-lipid
34:0, I-lipid
PE B-lipid
34:0, I-lipid
PG B-lipid
34:0, I-lipid
PS B-lipid
34:0, I-lipid
DG B-lipid
34:0, I-lipid
SM B-lipid
30:1;O2, I-lipid
TG B-lipid
51:0 I-lipid
and O
3.2 O
μM O
of O
D6-CE O
18:0, O
D6-FC O
and O
0.125 O
μM O
of O
SPB B-lipid
17:1;O2 I-lipid
and O
0.5 O
μM O
of O
S1P O
17:1, O
CER O
18:1/17:0, O
D3-GlcCER O
18:1/16:0 O
and O
0.25 O
μM O
of O
D3-LacCER O
18:1/16:0, O
Gb3 O
18:1/17:0. O

Pyruvic O
acid, O
Succinic O
acid, O
Malonic O
acid, O
FA B-lipid
16:0 I-lipid
and O
Arachidonic O
acid O
constitute O
the O
most O
significant O
sub O
nodes. O

Platelets, O
common O
sources O
of O
MVs, O
have O
been O
shown O
to O
externalize O
PS B-lipid
36:1 I-lipid
and O
PS B-lipid
38:4 I-lipid
from O
the O
inner O
to O
outer O
membrane O
when O
activated O
by O
thrombin. O

Lipid O
peroxidation, O
quantitation, O
FAL B-lipid
9:1;O, I-lipid
FAL B-lipid
9:2;O, I-lipid
mass O
spectrometry, O
smoking O

For O
instance, O
PC B-lipid
33:0 I-lipid
was O
found O
to O
exhibit O
significant O
changes O
in O
sn O
-ratios O

Additionally, O
among O
females, O
PC B-lipid
40:6, I-lipid
PE B-lipid
38:6, I-lipid
PE B-lipid
40:6 I-lipid
and O
PE B-lipid
40:7 I-lipid
correlated O
with O
enzymatically O
assayed O
TG O
levels O
(r O
= O
0.48, O
0.48, O
0.59 O
and O
0.43 O
respectively, O
p<0.01), O
while O
PE O
38:6, O
PE O
40:6 O
and O
PE O
40:7 O
were O
also O
negatively O
correlated O
with O
LDL-C O
levels O
(r O
= O
-0.37, O
-0.35, O
and O
-0.46 O
respectively, O
p<0.02) O
independent O
of O
age O
and O
BMI. O

Manual O
interpretation O
of O
the O
fragments O
showed O
that O
while O
FA B-lipid
22:6;O I-lipid
has O
four O
double O
bonds O
between O
carbons O
11 O
and O
22, O
this O
potentially O
novel O
oxylipin O
only O
has O
three. O

These O
7 O
metabolites O
were O
acetone, O
2-butanone, O
4-heptanone, O
dimethyl O
disulfide, O
furan, O
FAL B-lipid
5:0 I-lipid
and O
2-methylpyrazine. O

Furthermore, O
the O
increase O
of O
pyruvate O
could O
be O
mediated O
through O
the O
methylcitrate O
cycle O
(MCC), O
which O
oxidizes O
CoA B-lipid
3:0 I-lipid
generated O
by O
β-oxidation O
of O
odd-chain O
fatty O
acids O
to O
pyruvate O
, O
which O
then O
feed O
into O
the O
TCA O
cycle O
_, O
. O

Moreover, O
serum O
levels O
of O
LPC B-lipid
18:2, I-lipid
PhePhe, O
uridine, O
taurine, O
L-threonine, O
and O
FA B-lipid
16:0;O I-lipid
were O
significantly O
correlated O
with O
clinical O
activity O
scores O
(all O
p<0.05) O
in O
AOSD O
patients. O

Regarding O
phosphatidylglycerol O
(PGs), O
which O
a O
phosphoglycerol O
moiety O
occupies O
a O
glycerol O
substitution O
site, O
little O
evidence O
has O
been O
shown O
on O
their O
relationship O
with O
CHD, O
and O
we O
were O
the O
first O
to O
reveal O
a O
positive O
relationship O
between O
PG B-lipid
22:3 I-lipid
and O
CHD O
(OR: O
3.938; O
95% O
CI: O
(1.891, O
8.204); O

The O
1.22 O
± O
0.09 O
mmol/l O
(173 O
± O
6.09%) O
increase O
in O
total O
PC O
after O
the O
rHDL O
infusion O
could O
be O
attributed O
to O
the O
34:3, O
34:2, O
36:3, O
and O
36:2 O
species; O
however, O
the O
expected O
increase O
in O
PC B-lipid
36:4 I-lipid
was O
not O
observed. O

AA O
metabolites O
were O
further O
extracted O
and O
subjected O
to O
LC–MS/MS, O
as O
described O
in O
Materials O
and O
Methods O
to O
detect O
levels O
of O
FA B-lipid
20:4;O. I-lipid

FA B-lipid
4:0 I-lipid
was O
increased O
in O
responders O
(FC: O
2.30, O
p O
= O
0.041), O
which O
is O
a O
direct O
agonist O
of O
the O
G-protein O
coupled O
receptor O
(GPCR), O
hydroxycarboxylic O
acid O
receptor O
2 O
(HCA_2 O
) O
to O
induce O
vasodilation O
and O
inhibit O
atherosclerotic O
activity. O

Linoleate/arachidonate-derived O
lipid O
signalling O
molecules O
13-HODE+9-HODE O
(2.54-fold O
increase O
in O
HCC:DC), O
FA B-lipid
20:4;O I-lipid
(2.8 O
↑) O
and O
FA O
20:4;O O
(1.7 O
↑) O
exhibited O
elevation O
in O
HCC O
vs. O
DC. O

S2G O
); O
glycerophosphoserine O
38:4, O
PS B-lipid
38:4 I-lipid
at O
m O
/z O
810.6 O
(SI O
Appendix O
, O
Fig. O

ST B-lipid
27:1;O, I-lipid
which O
is O
essential O
for O
parasite O
intra-erythrocytic O
growth O
(Bansal O
et O
al. O
) O
and O
infection O
(Samuel O
et O
al. O
), O
is O
also O
fully O
obtained O
from O
the O
host. O

Given O
that O
PC B-lipid
34:1 I-lipid
was O
the O
dominant O
component O
(94%), O
HILIC-PB-MS_2 O
CID O
in O
positive O
ion O
mode O
readily O
provided O
CC O
location O
information, O
viz. O

Prior O
to O
ozone O
introduction, O
the O
main O
features O
in O
the O
mass O
spectrum O
are O
the O
protonated O
(m/z O
786), O
sodiated O
(m/z O
808) O
and O
potassiated O
(m/z O
824) O
adducts O
of O
PC B-lipid
36:2. I-lipid

A O
recent O
lipidomics O
study O
of O
human O
acquired O
obesity O
found O
increased O
adipose O
tissue O
levels O
of O
FA B-lipid
20:5, I-lipid
a O
precursor O
of O
anti-inflammatory O
related O
FA B-lipid
22:6 I-lipid
(DHA). O

We O
highlight O
that O
none O
of O
the O
markers O
identified O
in O
this O
study O
have O
previously O
been O
related O
to O
CRC O
with O
the O
exception O
of O
LPC B-lipid
18:1. I-lipid

In O
the O
LC O
group, O
18 O
metabolites O
had O
significantly O
lower O
peak O
intensities O
than O
in O
the O
control O
group; O
glycolic O
acid O
(q O
= O
1.112 O
× O
10_–11 O
), O
myristic O
acid O
(q O
= O
0.019), O
FA B-lipid
14:1;O3 I-lipid
(q O
= O
0.025), O
α-linolenic O
acid O
(q O
= O
1.877 O
× O
10_–5 O
), O
linoleic O
acid O
(q O
= O
3.805 O
× O
10_–5 O
), O
oleic O
acid O
(q O
= O
0.025), O
FA B-lipid
18:4;O I-lipid
(q O
= O
0.001), O
FA B-lipid
18:2;O I-lipid
(q O
= O
3.326 O
× O
10_–5 O
), O
9-cis-retinoic O
acid O
(q O
= O
7.158 O
× O
10_–6 O
), O
FA B-lipid
20:5 I-lipid
(q O
= O
5.311 O
× O
10_–5 O
), O
FA B-lipid
20:5;O I-lipid
(q O
= O
3.021 O
× O
10_–6 O
), O
FA B-lipid
20:4;O I-lipid
(q O
= O
4.986 O
× O
10_–7 O
), O
leukotriene O
B_4 O
(q O
= O
3.412 O
× O
10_–4 O
), O
17-HdoHE O
(q O
= O
4.587 O
× O
10_–7 O
), O
dehydroepiandrosterone O
sulfate O
(q O
= O
9.100 O
× O
10_–4 O
), O
LPA B-lipid
16:0 I-lipid
(q O
= O
0.005), O
LPA B-lipid
18:1 I-lipid
(q O
= O
2.097 O
× O
10_–5 O
), O
and O
PE B-lipid
O-16:1 I-lipid
(q O
= O
4.878 O
× O
10_–5 O
). O

The O
relationship O
observed O
in O
univariate O
analysis O
between O
insulin O
and O
glycine O
(negative O
correlation), O
glutamic O
acid O
(positive O
correlation) O
and O
FA B-lipid
4:0;O I-lipid
(negative O
correlation) O
was O
also O
observed O
in O
the O
multivariate O
analysis. O

Of O
the O
six O
metabolites O
we O
obtained O
reproducible O
results O
for O
quantitative O
evaluation O
of O
three O
metabolites O
PC B-lipid
32:0, I-lipid
PC B-lipid
40:4, I-lipid
and O
SM B-lipid
34:1;O2 I-lipid
while O
the O
PE B-lipid
17:0 I-lipid
levels O
in O
the O
plasma O
samples O
were O
lower O
than O
the O
lower O
limit O
of O
quantification O
(LOQ). O

The O
exclusive O
increase O
of O
PC B-lipid
32:0 I-lipid
supports O
fatty O
liver O
disease O
with O
EVD, O
as O
PC O
32:0 O
was O
recently O
reported O
as O
a O
potential O
signature O
of O
progressive O
forms O
of O
fatty O
liver O
disease. O

A O
previous O
pilot O
analysis O
also O
showed O
markedly O
greater O
extraction O
of O
the O
highly O
polar O
lipid O
standards, O
phosphatidylserine, O
PS B-lipid
34:0 I-lipid
and O
sphingosine O
phosphate, O
SoP(d17:1) O
in O
the O
Alshehry O
method O
compared O
to O
either O
the O
Matyash O
or O
Folch O
methods. O

We O
hereby O
report O
that O
the O
altered O
lipids O
PC B-lipid
39:6 I-lipid
and O
FA B-lipid
22:3 I-lipid
offer O
a O
new O
set O
of O
biomarkers O
in O
addition O
to O
the O
existing O
diagnostic O
tests O
that O
could O
significantly O
improve O
sensitivity O
and O
specificity O
in O
PCa O
diagnosis. O

In O
the O
schizophrenia O
cohort, O
significant O
differences O
were O
apparent O
in O
several O
saturated O
FA, O
such O
as O
16:0 O
(palmitic O
acid), O
14:0 O
(myristic O
acid), O
24:0 O
(lignoceric O
acid), O
and O
the O
unsaturated O
essential O
FA B-lipid
18:2 I-lipid
(linoleic O
acid). O

However, O
only O
TG B-lipid
49:1 I-lipid
and O
TG B-lipid
51:1 I-lipid
were O
identified O
as O
putative O
biomarkers O
when O
the O
lipidome O
was O
compared O
between O
meloxicam- O
and O
saline-treated O
cats O
and O
within O
the O
meloxicam O
group O
(post-treatment O
vs O
baseline O
lipidome) O

For O
instance, O
the O
peak O
at O
m/z O
718.6 O
in O
141 Da O
NLS O
(monoisotopic O
molecular O
mass: O
717.6 Da, O
RT: O
5.2 min) O
was O
identified O
as O
PE B-lipid
34:1, I-lipid
based O
on O
the O
detection O
of O
fatty O
acyl O
anions O
at O
m/z O
255 O
(C16:0) O
and O
m/z O
281 O
(C18:1) O
(Supplementary O
Fig. O

10-HdoHE, O
FA B-lipid
20:5;O, I-lipid
and O
FA B-lipid
22:6;O I-lipid
are O
examples O
of O
potentially O
anti-inflammatory O
ω-3 O
fatty O
acids O
[, O
]. O

Six O
lipids, O
TG B-lipid
51:1, I-lipid
TG B-lipid
49:1, I-lipid
TG B-lipid
56:6, I-lipid
TG B-lipid
48:1, I-lipid
TG O
(54:6)B O
and O
SM O
(d42:2)A O
were O
identified O
as O
potential O
biomarker O
candidates O
for O
monitoring O
meloxicam-treated O
cats. O

In O
the O
differential O
diagnosis O
of O
cirrhosis O
and O
early O
stage O
HCC, O
the O
AUCs O
of O
LysoPC O
[18:2 O
(9Z,12Z)], O
LysoPC O
(FA O
O-16:1), I-lipid
asparaginyl-proline O
and O
vaccenic O
acid O
were O
increased O
compared O
with O
that O
of O
AFP. O

In O
addition, O
40% O
(2/5) O
of O
the O
unsaturated O
fatty O
acids O
(bishomo-gamma-linolenic O
acid O
and O
FA B-lipid
22:6 I-lipid
(DHA)) O
were O
increased, O
but O
others O
including O
FA B-lipid
20:3, I-lipid
arachidonic O
acid, O
and O
FA B-lipid
20:5 I-lipid
(EPA) O
were O
decreased. O

New O
SM O
molecules O
were O
most O
probably O
generated O
from O
degraded O
PC O
compounds O
by O
SM O
synthase O
(this O
transferase O
utilizes O
a O
choline O
“head” O
from O
PC) O
and O
suitable O
ceramide O
molecules, O
which O
was O
coherent O
with O
observed O
down-regulation O
of O
Cer B-lipid
36:2;O2. I-lipid

Although O
this O
study O
targeted O
lung O
cancer, O
and O
the O
mechanism O
by O
which O
FA B-lipid
9:0 I-lipid
levels O
increase O
remains O
unclear, O
FA O
9:0 O
might O
be O
a O
biomarker O
for O
detecting O
OSCC. O

It O
was O
revealed O
that O
under O
certain O
conditions, O
B-CLL O
cells O
have O
equal O
capacity O
to O
myeloid O
cells O
to O
biosynthesise O
and O
release O
FA B-lipid
20:4;O2. I-lipid

The O
majority O
of O
PLs O
identified O
in O
this O
work, O
including O
different O
PCs O
and O
LPCs O
as O
well O
as O
SM B-lipid
34:1;O2, I-lipid
belong O
to O
the O
most O
abundant O
in O
their O
classes O
measured O
in O
human O
plasma O
samples; O
SM B-lipid
38:3;O2 I-lipid
and O
Cer B-lipid
36:2;O2 I-lipid
are O
less O
common O
species. O

In O
the O
m O
/z O
region O
of O
sn O
-1 O
fragment O
ions, O
detection O
of O
ions O
at O
m O
/z O
391 O
(sn O
-1 O
14:0), O
m O
/z O
405 O
(sn O
-1 O
15:0), O
and O
m O
/z O
419 O
(sn O
-1 O
16:0) O
proved O
that O
PC B-lipid
30:0 I-lipid
contained O
three O
molecular O
species: O
PC O
30:0, O
PC O
30:0, O
and O
PC O
30:0. O

The O
pairplot O
demonstrates O
the O
abundance O
of O
the O
two O
monohydroxy O
fatty O
acids O
12-HEPE O
and O
FA B-lipid
20:5;O I-lipid
at O
baseline O
levels O
before O
the O
surgery O
(T0) O
and O
24 O

In O
the O
esterified O
PUFA O
categories, O
there O
was O
significant O
postprandial O
reduction O
in O
abundance O
of O
several O
n-3 O
PUFAs, O
particularly O
FA B-lipid
22:6 I-lipid
(DHA), O
FA B-lipid
22:5 I-lipid
(DPA), O
and O
FA B-lipid
20:5 I-lipid
(EPA), O
and O
in O
n-6 O
PUFA, O
dihomo-γ-linolenic O
acid O
(DGLA). O

It O
is O
worth O
mentioning O
that O
four O
analytes O
FA B-lipid
18:2;O, I-lipid
FA O
18:2;O, O
9,10,13-TriHOME O
and O
9,12,13-TriHOME O
showed O
good O
sensitivity, O
but O
large O
variations O
were O
observed O
for O
the O
concentrations O
between O
LOQs O
and O
LLOQs O
(data O
not O
shown), O
which O
will O
require O
further O
investigation. O

The O
small O
sample O
size O
of O
the O
individual O
lymphoma O
subtypes O
prevented O
obtaining O
PLS-DA O
validated O
models, O
although O
specific O
peculiar O
features O
of O
each O
subtype O
were O
observed; O
for O
instance, O
fatty O
acids O
were O
most O
represented O
in O
MM O
and O
HL O
patients, O
while O
2-aminoadipic O
acid, O
FA B-lipid
7:1;N;O2, I-lipid
erythritol, O
and O
threitol O
characterized O
DLBCL O
and O
CLL. O

For O
the O
Folch O
method, O
the O
1:10, O
1:20, O
and O
1:100 O
(v/v) O
sample-to-solvent O
ratios O
provided O
higher O
peak O
areas O
for O
Cer B-lipid
40:1;O2 I-lipid
and O
many O
LPC/PC O
lipid O
classes O
compared O
to O
the O
1:4 O
(v/v) O
sample-to-solvent O
ratio. O

 528.6; O
and O
PC B-lipid
40:2 I-lipid
at O
m/z O
= O
842.90. O

Significant O
amounts O
of O
cholesterol O
and O
TG B-lipid
52:4 I-lipid
were O
detected O
following O
MTBE O
extraction, O
and O
these O
could O
not O
be O
detected O
when O
methanol O
alone O
was O
used. O

